Clinical trial transparency: An assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe

Current Medical Research and Opinion

Volumn 30, Issue 3, 2014, Pages 395-405

  Rawal, Bina ^a   Deane, Bryan R ^b  

^a ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY   (United Kingdom)

^b Livewire Editorial Communications   (United Kingdom)

Author keywords

Clinical trials; Publication bias; Results disclosure; Transparency; Trial registration; Trial registries

Indexed keywords

NEW DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; EUROPE; INTERPERSONAL COMMUNICATION; REGISTRATION;

CLINICAL TRIALS AS TOPIC; DISCLOSURE; DRUG INDUSTRY; EUROPE;

EID: 84896725237     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.860371     Document Type: Article

References (37)

1. Krleža-Jeric K, Chan A-W, Dickersin K, et al. for the Ottawa Group. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa Statement (part 1). BMJ 2005;330:956-8
2. World Medical Association. Declaration of Helsinki 2008 update - ethical principles for medical research involving human subjects. Adopted by the 59th WMA General Assembly, Seoul, Korea, October 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last Accessed 3 June 2013]
3. Mulrow CD. Rationale for systematic reviews. BMJ 1994;309:597-9
4. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated March 2011. The Cochrane Collaboration. Available at: http://www.cochrane-handbook.org [Last accessed 3 June 2013]
5. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8
6. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41
7. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008;5:e191
8. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217
9. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3:e3081
10. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:1-220
11. The PLOS Medicine Editors. Getting more generous with the truth; clinical trial reporting in 2013 and beyond. PLoS Med 2013;10:e1001379
12. Loder E, Godlee F, Barbour V, Winker M. Restoring the integrity of the clinical trials evidence base. BMJ 2013;346:f3601
13. Food and Drug Administration. Modernization Act of 1997. Public Law No 105-115
14. Food and Drug Administration. Amendments Act of 2007. Public Law No 110-85
15. Directive 2001/20/EC of the European Parliament and the Council of 4 Apr 2001 on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Community 2001;L121:34-44
16. Commission Guideline. Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Official J Eur Union 2012;C302:7-10
17. European Union Drug Regulating Authorities Clinical Trials database. Available at: https://eudract.ema.europa.eu/ [Last accessed 23 October 2013]
18. European Commission. (2012) Regulation of the European parliament and of the council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2012. Available at: http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=COM:2012:0369:FIN:EN:PDF [Last accessed 3 June 2013]
19. European Medicines Agency. (2013) Policy on proactive publication of clinical-trial data. Available at: http://www.ema.europa.eu/ema/index.jsp?-curl= pages/news-and-events/news/2013/06/news-detail-001825.jsp&mid= WC0b01ac058004d5c1 [Last accessed 16 August 2013]
20. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. CMAJ 2004;171:606-7
21. IFPMA Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases. 6 January 2005. Available at: http://clinicaltrials.ifpma.org/clinicaltrials/fileadmin/files/pdfs/FINAL%20 Position%20Clinical%20Trials%20Information%20January%2005.pdf [Last accessed 3 June 2013]
22. IFPMA Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases. Updated 10 November 2009. Available at: http://clinicaltrials.ifpma.org/clinicaltrials/fileadmin/files/pdfs/EN/ November-10-2009-Updated-Joint-Position-on-the-Disclosure-of-Clinical-Trial- Information-via-Clinical-Trial-Registries-and-Databases.pdf [Last accessed 3 June 2013]
23. IFPMA Joint Position on the Publication of Clinical Trial Results. 10 June 2010. Available at: http://clinicaltrials.ifpma.org/clinicaltrials/ fileadmin/files/pdfs/20100610-Joint-Position-Publication-10Jun2010.pdf [Last accessed 3 June 2013]
24. Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302: 977-84
25. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010;153:158-66
26. Ross JS, Mulvey GK, Hines EM, et al. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 2009;6:e1000144
27. Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results databaseupdate and key issues. N Engl J Med 2011;364:852-60
28. Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff (Milwood) 2011;30:2338-45
29. Gill CJ. How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the ClinicalTrials.gov database. BMJ Open 2012;2:e001186
30. Prayle AP, Hurley MN, Smith AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross-sectional study. BMJ 2012;344:d7373
31. Hawkes N. FDA disagrees with BMJ study that found clinical trials were not being reported. BMJ 2012;344:e3277
32. Wadman M. FDA says study overestimated non-compliance with datareporting laws. Nature 2012;10.1038/nature.2012.10549
33. Commons Select Committee. Committee to inquire into clinical trials and disclosure of data. 13 December 2012. Available at: http://www.parliament.uk/ business/committees/committees-a-z/commons-select/scienceand-technology- committee/news/121213-clinical-trials-inquiry-announced/ [Last accessed 3 June 2013]
34. Turner S, Wright D, Maeso R, et al. Publication rate for funded studies from a major UK health research funder: a cohort study. BMJ Open 2013;3:e002521
35. ABPI Clinical Trial Disclosure Toolkit. 2013. Available at: http://www.abpi.org. uk/our-work/mandi/Pages/clinical-trial-transparency.aspx [Last accessed 16 Aug 2013]
36. EU Clinical Trial Register. 2013 Frequently Asked Questions. Available at: http://www.clinicaltrialsregister.eu/doc/EU-CTR-FAQ.pdf [Last accessed 3 June 2013]
37. Huser V, Cimino JJ. Precision and negative predictive value of links between ClinicalTrials.gov and PubMed. AMIA Annu Symp Proc 2012;2012:400-8